

Express Mail Label No: EL728729076US
Date of Deposit: March 19, 2001
3-28-01

Atty. Docket No.: 4219/1340

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Russell, et al.
Serial No.: 09/043,665
Filed: October 5, 1998
Entitled: Materials and Methods Relating to
the Transfer of Nucleic Acid Into
Quiescent Cells

Examiner: R. Shukla, Ph.D.
Group Art Unit: 1632

RECEIVED

Commissioner for Patents
Washington, D.C. 20231

MAR 22 2001

AMENDMENT TRANSMITTAL LETTER

TECH CENTER 1600/2900

Sir:

1. Transmitted herewith is an amendment in response to the Office Action mailed
on in the above-referenced patent application.

STATUS

2. Applicant is
 a small entity.
 other than small entity.

EXTENSION OF TERM

3. The proceedings herein are for a patent application and the provisions of 37
CFR 1.136 apply.

<input type="checkbox"/> Applicant petitions for an extension of time under 37 CFR 1.136	Extension (months)	Fee for other than <u>small entity</u>	Fee for <u>small entity</u>
<input type="checkbox"/>	ONE month	\$110.00	\$55.00
<input type="checkbox"/>	TWO months	\$390.00	\$195.00
<input checked="" type="checkbox"/>	THREE months	\$890.00	\$445.00
<input type="checkbox"/>	FOUR months	\$1,390.00	\$695.00
<input type="checkbox"/>	FIVE months	\$1,890.00	\$945.00
		Fee	\$445.00

If an additional extension of time is required, please consider this a petition therefor.

03/21/2001 445.00 00000100 09043665

02 FC:217

445.00 0P



(a) An extension for _____ has already been secured and the fee paid therefor of \$ _____ is deducted from the total fee due for the total months of extension now requested.

Extension fee due with this request \$445.00

OR

(b) Applicant believes that no extension of term is required. However, this conditional petition is being made to provide for the possibility that applicant has inadvertently overlooked the need for a petition for extension of time.

FEE FOR CLAIMS

4. The fee for claims (37 CFR 1.16(b)-(d)) has been calculated as shown below:

CLAIMS AS AMENDED		(1)	(2)	(3)			
	CLAIMS REMAINING AFTER AMENDMENT			HIGHEST NUMBER PREVIOUSLY PAID FOR	PRESENT NUMBER EXTRA	RATE	FEE
TOTAL CLAIMS		minus				x \$18	
INDEPENDENT CLAIMS		minus				x \$80	
MULTIPLE DEPENDENT CLAIM ADDED	Yes/No				\$270		
				TOTAL			
If applicant has small entity status under 37 CFR 1.9 and 1.27, then divide total fee by 2 and enter amount here.				SMALL ENTITY TOTAL			


(c) No additional fee for claims is required.

OR

(d) Total additional fee for claims required \$

FEE PAYMENT

5. Attached is a check in the sum of \$445.00



Charge Deposit Account No. 16-0085, Reference No. 4219/1340 any additional necessary fees.
A duplicate of this transmittal is attached.

Respectfully submitted



Name: Mark J. Fitzgerald Ph.D.
Registration No.: 45,928 for
Kathleen M. Williams, Ph.D.
Registration No.: 34,380
Palmer & Dodge LLP
One Beacon Street
Boston, MA 02108
Tel: 617-573-0100



20/C
KP
3-28-01
A/E
PATENT

Express Mail Label No: EL728729076US
Date of Deposit: 3/19/2001

Response under 37 CFR § 1.116
--EXPEDITED PROCEDURE--
Examining Group 1600

THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Russell, et al.
U.S. Serial No.: 09/043,665
Filed (U.S.): October 5, 1998
Entitled: Materials and Methods Relating to the Transfer of Nucleic Acid Into Quiescent Cells

Attorney Docket No.: 4219/1340 (formerly 3789/81421)

Commissioner for Patents and Trademarks
Box AF
Washington, D.C. 20231

Group: 1632
Examiner: R. Shukla, Ph.D.

RECEIVED

MAR 22 2001

TECH CENTER 1600/2900

AMENDMENT UNDER 37 C.F.R. §1.116

Sir:

This amendment is filed in response to the Final Office Action mailed in the above-noted U.S. patent application on September 19, 2000. Please amend the application as indicated below.

In the Claims:

Please cancel claims 9 and 10.

Please replace claim 11 with the following:

11. (Amended) A method of treating a patient having a disease or disorder, the method comprising the steps of:

a) exposing a population of quiescent cells to a retroviral packaging cell line in vitro, said packaging cell line expressing nucleic acid encoding a growth factor so that the growth factor is displayed on the surface of the cell line, the cell line or retroviral particles carrying a vector